Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZPL-3893787 in Adult Moderate to Severe Atopic Dermatitis: Effect on Pruritus
2014-005057-39Phase 2Completed
- Sponsor
- Ziarco Pharma Ltd
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing ZPL-3893787 30 mg once daily with Placebo (2 arms). Primary endpoint: Change from baseline in Numerical Rating Score (NRS) for Pruritus (Worst Itch) over 24 hours. Started Feb 2015; status: completed.
02
Drugs
adriforant
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2014-005057-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005057-39.